C4 therapeutics presents cemsidomide phase 1 multiple myeloma data supporting potential best-in-class profile at the international myeloma society annual meeting

Cemsidomide in combination with dexamethasone achieved a 50% overall response rate (orr) at the highest dose level (100 Μg) and a 40% orr at the 75 Μg dose level in a heavily pre-treated relapsed/refractory multiple myeloma patient population

CCCC Ratings Summary

CCCC Quant Ranking